S. Settatree

Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100

The SWI/SNF ATPase Brm Is a Gatekeeper of Proliferative Control in Prostate Cancer

PARP inhibitors: Synthetic lethality in the clinic

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Discovery of a regioselectivity switch in nitrating P450s guided by molecular dynamics simulations and Markov models

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

Translating cancer research into targeted therapeutics

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

SWI/SNF nucleosome remodellers and cancer

Prostate cancer

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

Current and future perspectives of liquid biopsies in genomics-driven oncology

Antibody therapy of cancer

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer

Unraveling the therapeutic potential of the Hedgehog pathway in cancer

Androgen action and metabolism in prostate cancer

Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer

1,2,4-Oxadiazoles: A new class of anti-prostate cancer agents

Pancreatic Cancer

The Diagnosis of Polycystic Ovary Syndrome during Adolescence

Tumour heterogeneity and resistance to cancer therapies

Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals

Monoclonal Antibodies for Cancer Therapy

New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway

Tumor clone dynamics in lethal prostate cancer

Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer

The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer

Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box

A New Initiative on Precision Medicine

Cancer treatment and survivorship statistics, 2019

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Metastatic Prostate Cancer

Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer

Molecular Dynamic Investigations of the Mutational Effects on Structural Characteristics and Tunnel Geometry in CYP17A1

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

Cancer treatment and survivorship statistics, 2014

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

196 POSTER A phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer

An open, pharmacokinetic (PK) and mass balance study of ¹⁴C-AZD2171, incorporating DCE-CT evaluations